Del-desiran reduced DMPK mRNA levels, but led to two serious adverse events ...

Crinetics Pharmaceuticals Inc (CRNX) reports successful launch of Palsonfi and robust financial health, while navigating high R&D costs and market penetration challenges.

Preclinical results indicate new approach could be a way to deliver treatment directly to tumors at higher doses, while reducing side effects in healthy tissue.

Q4 2025 Earnings Call February 26, 2026 8:30 AM ESTCompany ParticipantsLuis Sanay - Vice President of Investor RelationsJohn Jacobs ...

Dr Parikh explained that KEYNOTE-B15 (NCT04700124) is evaluating the role of perioperative enfortumab vedotin (Padcev), an ...

For a few brief nights each year, you get a rare chance to watch a monster blink. The Event Horizon Telescope collaboration ...

IntoCell nears Samsung Bioepis deal as phase 1 starts, milestone hopes rise Phase 1 launch of Samsungs first in-house ADC could trigger IntoCell milestone payouts despite ongoing losses ...

Avacta's preCision platform is a proprietary payload delivery system designed to concentrate highly potent payloads in the tumour microenvironment while sparing normal tissues.

HER2-positive gastric cancer accounts for a substantial proportion of advanced cases and has long been treated with HER2-targeted therapies. While trastuzumab deruxtecan has shown superior activity ...

Under the morning sun, I climb the steep cobblestone streets of the Albaicín. It’s my second day volunteering in music classes at the local primary school. Upon entering Colegio Público Gomez-Moreno, ...

Gilead has secured another synthetic lethal therapy, handing over $80 million upfront for the global rights to a clinic-ready cancer drug from China’s Genhouse Bio. | Gilead has secured another ...

For the last three years, Bayer has been implementing a new strategy for its oncology development, a strategy that led to multiple approvals, as well as a number of promising new programmes added to ...